

4'  
**HALE AND DORR** LLP  
C O U N S E L O R S   A T   L A W

haledorr.com

60 STATE STREET • BOSTON, MA 02109  
617-526-6000 • FAX 617-526-5000

1644  
\$  
RECEIVED

AUG 14 2003

TECH CENTER 16 12/2003

August 11, 2003

ATTN: Examiner R. Schwadron

Commissioner for Patents  
Washington, DC 20031

Re:   **Applicant:**   **JAKOBSEN et al.**  
      **Serial No.:**   **09/560,494**  
      **For:**         **CD8 AS AN INHIBITOR OF THE CELLULAR**  
                      **IMMUNE SYSTEM**  
      **Our Ref:**     **102286.413 US1**


Dear Sir:

Enclosed herewith for appropriate action by the United States Patent and Trademark Office are the following documents:

- [X] Transmittal Letter;
- [X] Response to Restriction Requirement and Amendment;
- [X] Petition for One-Month Extension of Time Under 37 C.F.R. § 1.136(a); and
- [X] postcard evidencing the same.

The Commissioner is authorized to charge the one-month extension time fee of \$110.00 and to charge any other fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of this application

Respectfully submitted,

  
Edward D. Grieff  
Attorney for Applicant  
Registration No. 38,898



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

JAKOBSEN et al.

SERIAL NO.: 09/560,494

FILED: 28 APRIL 2000

FOR: CD8 AS AN INHIBITOR OF THE  
CELLULAR IMMUNE SYSTEM

Commissioner for Patents  
Arlington, VA 22202

GROUP ART UNIT: 1644

EXAMINER: R. SCHWADRON

ATTY. DKT. NO. 102286.413 US1

RECEIVED

AUG 14 2003

TECH CENTER

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

This response is submitted in reply to the Office Action dated June 18, 2003, for which a response is due on or before August 18, 2003 with a one month extension. The Commissioner is authorized to charge the one month extension time fee of \$110.00 and to charge any other necessary fees or credit any overpayment to Deposit Account No. 08-0219 to maintain the pendency of this application. Please amend the above-identified application as follows:

**Amendments to the Claims** begin on page 2 of this paper.

**Remarks** begin on page 4 of this paper.